Clinical Trial Update: LEE011 for Patients With CDK4/6 Pathway Activated Tumors (SIGNATURE) [Phase 2]

View source ↗

Summary

Phase 2 trial update for LEE011 in tumors with CDK4/6 pathway activation has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Tumors with Cdk4 6 Pathway Activation

Drugs mentioned

• LEE011 (ribociclib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Tumors With CDK4/6 Pathway Activation | Phase 2 | Status: COMPLETED | Results posted: 2019-04-16